Immunotherapy
From the Journals
Tumor neoantigenicity metric improves prediction of response to immunotherapy
A new scoring system can predict response to immunotherapy in patients with melanoma, lung cancer, and kidney cancer.
Video
Experts break down latest CAR T-cell advances in lymphoma
ORLANDO – An expert panel of physicians discusses the latest research on CAR T-cell therapy in lymphoma, presented at the 2019 annual meeting of...
From the Journals
New toxicity subscale measures QOL in cancer patients on checkpoint inhibitors
With further validation, the instrument could become an important tool for evaluation of treatment-related toxicity.
Conference Coverage
CAR T cells produce complete responses in T-cell malignancies
ORLANDO – There were no cases of severe cytokine release syndrome or severe neurotoxicity reported with the anti-CD5 chimeric antigen receptor T...
Conference Coverage
CAR T-cell therapy advances in CLL
ORLANDO – The safety and clinical activity of the CD19-directed CAR T-cell agent justifies moving forward with phase 2 investigation, researchers...
Conference Coverage
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients
ORLANDO – All 10 patients responded to anti-BCMA CAR T-cell therapy, including 3 patients who had previously failed BCMA-directed therapy.
Conference Coverage
Survival data reported from largest CAR T trial in B-cell lymphoma
ORLANDO – Progression-free survival results were best among complete responders and patients with primary mediastinal large B-cell lymphoma or...
Conference Coverage
‘Real-world’ data show CAR T therapies are cost effective
ORLANDO – An analysis of Medicare claims data found that treatment with CAR T-cell therapy was associated with fewer hospitalizations and shorter...
Conference Coverage
An off-the-shelf drug to rival CAR T cells: ‘very exciting’
ORLANDO – Mosunetuzumab is a bispecific antibody that targets both CD3 and CD20. It was tested in a phase 1/1b trial among patients with relapsed/...
Conference Coverage
Off-the-shelf cellular therapy shows promise in the lab
ORLANDO – Findings from this preclinical research support moving forward with a phase 1 study of the therapy, as monotherapy or combined with...
Conference Coverage
Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma
ORLANDO – Duration of response, manageable safety support further investigation of dual-targeted strategy, according to investigator.